Bufotalidin

CAS : 465-90-7

Ref. 3D-AAA46590

Informations sur le produit

• Nom: Bufotalidin
• Synonymes: (3Beta,5Beta)-3,5,14-Trihydroxy-19-Oxobufa-20,22-Dienolide, (3Beta,5Beta,8Xi,9Xi)-3,5,14-Trihydroxy-19-Oxobufa-20,22-Dienolide, (3β,5β)-3,5,14-Trihydroxy-19-oxobufa-20,22-dienolide, 19-Oxo-3-beta,5,14-trihydroxy-5-beta-bufa-20,22-dienolide, 5-beta-Bufa-20,22-dienolide, 3-beta,5,14-trihydroxy-19-oxo-, 5β-Bufa-20,22-dienolide, 3β,5,14-trihydroxy-19-oxo-, Brn 0056259, Bufa-20,22-dienolide, 3,5,14-trihydroxy-19-oxo-, (3beta,5beta)-, Gellebrigenin, Hellebrigenin, Nsc 89594, Bufa-20,22-dienolide, 3,5,14-trihydroxy-19-oxo-, (3β,5β)-, 5-18-05-00180 (Beilstein Handbook Reference)

Description

Bufotalidin is a caffeic acid derivative that has been shown to have inhibitory properties on the heart and locomotor activity. Bufotalidin was shown to decrease the cardiac contractility of isolated rat hearts by inhibiting calcium influx. It also inhibits basic protein kinase C (PKC) in HL-60 cells, which may be due to its ability to inhibit PKC translocation from the cytosol to the membrane. Bufotalidin also has an inhibitory effect on autophagy, which is a process that breaks down cellular components. The molecular mechanisms underlying these effects are not yet understood.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 416.51 g/mol
• Formule: C₂₄H₃₂O₆
• Degré de pureté: Min. 95%